Novo Nordisk, the Denmark-based health care company, is planning to invest $4.1 billion to expand its U.S. manufacturing capacity with a second fill and finishing facility in Clayton, N.C.
Moving COVID-19 remedies through development, testing, production and global distribution has pharmaceutical and R&D firms and their industry designers and builders rushing to maximize space and productivity.
